Cargando…

Nanobubbles Containing sPD-1 and Ce6 Mediate Combination Immunotherapy and Suppress Hepatocellular Carcinoma in Mice

PURPOSE: Immune checkpoint inhibitors (ICIs) and sonodynamic therapy (SDT) are types of immunotherapy. In order to combine soluble programmed cell death protein 1 (sPD-1)-mediated immune checkpoint therapy and chlorin e6 (Ce6)-assisted SDT, nanobubbles (NBs) were generated to simultaneously load sPD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tan, Yandi, Yang, Shiqi, Ma, Yao, Li, Jinlin, Xie, Qian, Liu, Chaoqi, Zhao, Yun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8121678/ https://www.ncbi.nlm.nih.gov/pubmed/34007176 http://dx.doi.org/10.2147/IJN.S305857

Ejemplares similares

Nanobubble-based anti-hepatocellular carcinoma therapy combining immune check inhibitors and sonodynamic therapy
por: Liu, Yun, et al.
Publicado: (2022)

Targeted Nanobubbles of PD-L1 mAb Combined with Doxorubicin as a Synergistic Tumor Repressor in Hepatocarcinoma
por: Chen, Yezi, et al.
Publicado: (2022)

Can sPD-1 and sPD-L1 Plasma Concentrations Predict Treatment Response among Patients with Extraparenchymal Neurocysticercosis?
por: Toledo, Andrea, et al.
Publicado: (2023)

The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma
por: Chang, Boyang, et al.
Publicado: (2018)

On Some Aspects of Nanobubble-Containing Systems
por: Yasui, Kyuichi
Publicado: (2022)

Soluble programmed death-1 (sPD-1) and programmed death ligand 1 (sPD-L1) as potential biomarkers for the diagnosis and prognosis of glioma patients
por: Liu, Shujun, et al.
Publicado: (2020)

Clinical Relevance of Soluble Forms of Immune Checkpoint Molecules sPD-1, sPD-L1, and sCTLA-4 in the Diagnosis and Prognosis of Ovarian Cancer
por: Świderska, Janina, et al.
Publicado: (2022)

The correlation of serum sPD-1 and sPD-L1 levels with clinical, pathological characteristics and lymph node metastasis in nonsmall cell lung cancer patients
por: ANCIN, Burcu, et al.
Publicado: (2022)

Soluble Programmed Death Receptor Ligands sPD-L1 and sPD-L2 as Liquid Biopsy Markers for Prognosis and Platinum Response in Epithelial Ovarian Cancer
por: Buderath, Paul, et al.
Publicado: (2019)

Bulk Nanobubbles or Not Nanobubbles: That is the Question
por: Jadhav, Ananda J., et al.
Publicado: (2020)

Higher serum sPD-L1 levels after radiotherapy indicate poor outcome in hepatocellular carcinoma patients
por: Zhang, Yang, et al.
Publicado: (2022)

The association between sPD-1 levels versus liver biochemistry and viral markers in chronic hepatitis B patients: a comparative study of different sPD-1 assays
por: Jeng, Wen-Juei, et al.
Publicado: (2022)

Tumor growth suppression by the combination of nanobubbles and ultrasound
por: Suzuki, Ryo, et al.
Publicado: (2016)

Upregulation of PD-1 Expression and High sPD-L1 Levels Associated with COVID-19 Severity
por: Beserra, Danielle Rosa, et al.
Publicado: (2022)

Correlation of sPD1 with Procalcitonin and C-Reactive Protein Levels in Patients with Sepsis
por: Bakhshiani, Zahra, et al.
Publicado: (2021)

Backsplash Testbeam results for the SPD
por: Aguiló, E, et al.
Publicado: (2004)

Backsplash simulation and occupancies for the SPD
por: Aguiló, E, et al.
Publicado: (2003)

Hollow carbon nanobubbles: monocrystalline MOF nanobubbles and their pyrolysis
por: Zhang, Wei, et al.
Publicado: (2017)

Metastable Nanobubbles
por: Vehmas, Tapio, et al.
Publicado: (2021)

Pulseshape simulations for the SPD subdetector in LHCb
por: Aguiló, E
Publicado: (2004)

Backsplash simulation for the SPD (LHCb subdetector)
por: Calvo, M
Publicado: (2004)

A BICMOS discriminator interface for the SPD
por: Diéguez, A, et al.
Publicado: (2000)

The ALICE Silicon Pixel Detector (SPD)
por: Meddi, F
Publicado: (2000)

SPD Very Front End Electronics
por: Luengo, Sonia, et al.
Publicado: (2005)

Backsplash studies for the SPD subdetector of LHCb
por: Calvo-Gomez, Miriam
Publicado: (2006)

Soluble sPD-L1 and Serum Amyloid A1 as Potential Biomarkers for Lung Cancer
por: Jovanović, Dragana, et al.
Publicado: (2019)

Ultrasound combined with nanobubbles promotes systemic anticancer immunity and augments anti-PD1 efficacy
por: Hu, Jianjun, et al.
Publicado: (2022)

Ultrasound-Mediated Co-Delivery of miR-34a and sPD-1 Complexed with Microbubbles for Synergistic Cancer Therapy
por: Qin, Yu-e, et al.
Publicado: (2020)

The Caenorhabditis elegans pericentriolar material components SPD-2 and SPD-5 are monomeric in the cytoplasm before incorporation into the PCM matrix
por: Wueseke, Oliver, et al.
Publicado: (2014)

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
por: Li, Qian, et al.
Publicado: (2022)

Correction to “Metastable Nanobubbles”
por: Vehmas, Tapio, et al.
Publicado: (2021)

From Bubbles to Nanobubbles
por: Kyzas, George Z., et al.
Publicado: (2021)

The Clinical Significance of Soluble Programmed Cell Death-Ligand 1 (sPD-L1) in Patients With Gliomas
por: Liu, Shujun, et al.
Publicado: (2020)

Serum sPD1 and sPDL1 as Biomarkers for Evaluating the Immune State of Lung Adenocarcinoma Patients
por: Wu, Yumin, et al.
Publicado: (2022)

Generating Bulk Nanobubbles in Alcohol Systems
por: Ji, Yuwen, et al.
Publicado: (2021)

Discriminator ASIC for the SPD VFE of the LHCb calorimeter
por: Aguiló, E, et al.
Publicado: (2004)

Integration and test of the ALICE SPD readout chain
por: Boccardi, Andrea, et al.
Publicado: (2004)

Experimental performance of SPD/PS detector prototypes
por: Filippov, S, et al.
Publicado: (2000)

Using the SPD multiplicity in the Level-0 trigger
por: Callot, O, et al.
Publicado: (2003)

Backsplash Effects on SPD and Flavour Tagging in LHCb
por: Calvo-Gomez, M
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_geiv14o1o5cjocemlt7i6q87tn